STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (fg-27)	CAMIDANLUMAB TESIRINE
PRONUNCIATION	kam" i dan' lue mab tes ir' een
THERAPEUTIC CLAIM	Treatment of hematologic cancers

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(human interleukin 2 receptor α chain)(human HuMax-TAC heavy chain), human HuMax-TAC light chain, dimer, thioether with *N*-[31-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1,29-dioxo-4,7,10,13,16,19,22,25-octaoxa-28-azahentriacont-1-yl]-L-valyl-N-[4-[[[[(11*S*,11a*S*)-8-[[5-[[(11a*S*)-5,11a-dihydro-7-methoxy-2-methyl-5-oxo-1*H*-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl]oxy]pentyl]oxy]-11,11a-dihydro-11-hydroxy-7-methoxy-2-methyl-5-oxo-1*H*-pyrrolo[2,1-c][1,4]benzodiazepine-10(5*H*)-yl]carbonyl]oxy]methyl]phenyl]-L-alaninamide

2. Immunoglobulin G1-kappa, anti-[*Homo sapiens* Interleukin-2 receptor subunit alpha (TAC antigen, p55, CD25 antigen)], *Homo sapiens* monoclonal antibody conjugated to an average of two molecules of tesirine; γ1 heavy chain (1-445) [*Homo sapiens* VH (IGHV1-69*02 (95%) –(IGHD)-IGHJ4*01 (93%)) [8.8.8] (1-115) -*Homo sapiens* IGHG1*03 (116-445)], (218-214')-disulfide with κ light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (99%) –IGKJ4*01)[6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimer (224-224":227-227")-bisdisulfide, an average of two cysteines are *S*-linked to (1^{11a}*S*,9^{11}*S*,9^{11a}*S*,16*S*,19*S*,52^{3}*RS*)-9^{11}-hydroxy-1^{7}, 9^{7}-dimethoxy-1^{2},9^{2},16-trimethyl-1^{5},9^{5},10,15,18,21,49,52^{2}-52^{5}-nonaoxo-19-(propan-2-yl)-1^{5},1^{11a},9^{11},9^{11a}-tetrahydro-1^{1}*H*,9^{1}*H*,9^{5}*H*-2,8,11,24,27,30,33,36,39,42,45-undecaoxa-14,17,20,48-tetraaza-1(8),9(8,10)-bis(pyrrolo[2,1-*c*][1,4]benzodiazepine)-52(1)-pyrrolidina-13(1,4)benzenadopentacontaphan-52^{3}-yl

STRUCTURAL FORMULA

Heavy chain

QVQLVQSGAE	VKKPGSSVKV	SCKASGGTFS	RYIINWVRQA	PGQGLEWMGR	50
IIPILGVENY	AQKFQGRVTI	TADKSTSTAY	MELSSLRSED	TAVYYCARKD	100
WFDYWGQGTL	VTVSSASTKG	PSVFPLAPSS	KSTSGGTAAL	GCLVKDYFPE	150
PVTVSWNSGA	LTSGVHTFPA	VLQSSGLYSL	SSVVTVPSSS	LGTQTYICNV	200
NHKPSNTKVD	KRVEPKSCDK	THTCPPCPAP	ELLGGPSVFL	FPPKPKDTLM	250
ISRTPEVTCV	VVDVSHEDPE	VKFNWYVDGV	EVHNAKTKPR	EEQYNSTYRV	300
VSVLTVLHQD	WLNGKEYKCK	VSNKALPAPI	EKTISKAKGQ	PREPQVYTLP	350
PSREEMTKNQ	VSLTCLVKGF	YPSDIAVEWE	SNGQPENNYK	TTPPVLDSDG	400
SFFLYSKLTV	DKSRWQQGNV	FSCSVMHEAL	HNHYTQKSLS	LSPGK	445

Light chain

EIVLTQSPGT	LSLSPGERAT	LSCRASQSVS	SYLAWYQQKP	GQAPRLLIYG	50'
ASSRATGIPD	RFSGSGSGTD	FTLTISRLEP	EDFAVYYCQQ	YGSSPLTFGG	100'
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSKD	STYSLSSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

Disulfide bridges

22-96	22"-96"	23'-88'	23'"-88'"	134'-194'	134'"-194'"	142-198	142"-198"
214'-218*	214'"-218"*	224-224"*	227-227'"*	259-319	259"-319"	365-423	365"-423"

* one or two of the inter-chain disulfide bridges are not present, an average of two Cysteines are S-substituted with tesirine C.

Modified residues (C)



Glycosylation sites (N)

Asn-295 Asn-295"

MOLECULAR FORMULA	$C_{6548}H_{10150}N_{1732}O_{2038}S_{42}$
MOLECULAR WEIGHT	147.1 kDa
TRADEMARK	None as yet
SPONSOR	ADC Therapeutics SA
CODE DESIGNATIONS	ADCT-301
CAS REGISTRY NUMBER	1853239-04-9
UNII	LYJ1AEJ9YH
WHO NUMBER	10592

gbk